La chaîne d'options affiche les données clés des options sur actions de Molecular Partners à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Molecular Partners..

Molecular Partners (NASDAQ:MOLN) Stock, Chaîne d'Options

Molecular Partners

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG - American Depositary Shares

Molecular Partners AG

News

Press Releases

Molecular Partners to hold three poster presentations at AACR 2025

Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Health Care

Molecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025

Earnings

Molecular Partners Reports Financial Results and Highlights from Q1 2025

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

General

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Management

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics

Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025

MOLN

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Agenus

Anika Therapeutics

Biomea Fusion

Compugen

Climb Bio

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals

Cardiff Oncology

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

MDxHealth

Nkarta

Nuvectis Pharma

Oncolytics Biotech

Pyxis Oncology

AVITA Medical

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Skye Bioscience

Instil Bio

Tevogen Bio Holdings

JP Morgan

LifeSci Capital

Comments

Molecular Partners

Molecular Partners (MOLN) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL